Sign In
Buy KMDA
$7.14
+0.0400 (+0.563%)
At Close: Jul 31, 2026
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its pivotal Phase 3 InnovAATe clinical trial
Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a binding term sheet for a 12-year contract manufacturing agreement w
Kamada Wins a 12 Year Supply Contract Which is Expected to Add $8-$10M of Annual Revenue
12:00am, Monday, 09'th Dec 2019Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel
12:00pm, Monday, 02'nd Dec 2019
Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosi
Did Hedge Funds Drop The Ball On Kamada Ltd (KMDA) ?
03:04pm, Saturday, 30'th Nov 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and the
